Posted On: 06/13/2016 5:33:16 PM
Post# of 72447
Re: thefamilyman #24033
J&J would be my first guess because they aren't developing any antibiotic drugs. I mentioned the following article before.
"In December, Stoffels' company won regulatory approval for a new treatment for drug-resistant tuberculosis — a growing issue in many countries. But Johnson & Johnson is not developing any more antibiotics. "
http://articles.chicagotribune.com/2013-03-19...eria-ketek
J&J's current pipeline:
http://files.shareholder.com/downloads/JNJ/15...peline.pdf
"In December, Stoffels' company won regulatory approval for a new treatment for drug-resistant tuberculosis — a growing issue in many countries. But Johnson & Johnson is not developing any more antibiotics. "
http://articles.chicagotribune.com/2013-03-19...eria-ketek
J&J's current pipeline:
http://files.shareholder.com/downloads/JNJ/15...peline.pdf
Quote:
On top of that, if J&J (or whoever) is getting positive results from testing B as a medical device coating... Do you think perhaps a J&J type BP might decide that they need to go ahead and secure the Brilacidin franchise and it's $10 Billion+ in annual revenue potential?
(1)
(0)
